Raquel Gomez-Eerland

AstraZeneca (Netherlands) — Netherlands

Medicine · Health Sciences

16h-index2.9kcitations27works9.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(19), Immunotherapy and Immune Responses(11), Cancer Immunotherapy and Biomarkers(8), Virus-based gene therapy research(7), Immune Cell Function and Interaction(6)

Publications27 total

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies
Nature Communications·2025· 9 citedOpen Access
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1
Cancer Cell·2023· 40 citedOpen Access
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
Immuno-Oncology Technology·2022· 36 citedOpen Access
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
Journal for ImmunoTherapy of Cancer·2020· 185 citedOpen Access
CD29 identifies IFN-γ–producing human CD8 <sup>+</sup> T cells with an increased cytotoxic potential
Proceedings of the National Academy of Sciences·2020· 118 citedOpen Access
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Cell·2020· 41 citedOpen Access
Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma
Annals of Oncology·2019· 6 citedOpen Access
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Cell·2019· 253 citedOpen Access
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy
Nature Medicine·2019· 236 citedOpen Access
CD29 marks superior cytotoxic human T cells
2019· 6 citedOpen Access
SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
PLoS ONE·2019· 50 citedOpen Access
Abstract B205: Adoptive transfer of autologous T-cells, modified with a MART-1 specific TCR and cultured in IL-7/IL-15, for the treatment of metastatic melanoma patients
Cancer Immunology Research·2019
Abstract B188: CMTM6, beyond a regulator of PD-L1 expression
Cancer Immunology Research·2019
Multicenter phase I/IIa study using T cell receptor gene therapy in metastatic melanoma.
Journal of Clinical Oncology·2018· 2 cited
Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes
Cell·2017· 278 citedOpen Access
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Nature·2017· 687 citedOpen Access
Abstract LB-291: Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Cancer Research·2017
A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products
Molecular Therapy — Nucleic Acids·2016· 3 citedOpen Access
Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor
Molecular Therapy·2015· 106 citedOpen Access
Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype
Human Gene Therapy Methods·2014· 62 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Ton N. Schumacher(26), John B.A.G. Haanen(14), Christian U. Blank(10), Riccardo Mezzadra(8), Joost H. van den Berg(7), Bastiaan Nuijen(7), Thijn R. Brummelkamp(5), Noor A. M. Bakker(5), Bianca Heemskerk(5), Maaike van Zon(5), Renate de Boer(5), Jos H. Beijnen(5), Chong Sun(4), Albert J. R. Heck(4), Pia Kvistborg(4), Loes M. Pronk(4), Annelies Jorritsma(4), Maartje W. Rohaan(4), Lucas T. Jae(3), Wei Wu(3)